Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
about
Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme.Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNeuroinflammation in Alzheimer's diseaseβ-amyloid, microglia, and the inflammasome in Alzheimer's diseaseThe neuroprotective functions of transforming growth factor beta proteinsMechanisms of mononuclear phagocyte recruitment in Alzheimer's diseaseTREM2 and the neuroimmunology of Alzheimer's diseaseCurcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial CellsRetinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retinaLRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β.Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype.Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.Reimagining Alzheimer's disease--an age-based hypothesis.Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease.Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu.Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism.CXCL1 contributes to β-amyloid-induced transendothelial migration of monocytes in Alzheimer's disease.Amyloidogenic properties of a D/N mutated 12 amino acid fragment of the C-terminal domain of the Cholesteryl-Ester Transfer Protein (CETP).Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity.Nuclear receptors as therapeutic targets for Alzheimer's diseaseP2Y13 receptor-mediated rapid increase in intracellular calcium induced by ADP in cultured dorsal spinal cord microglia.Curcumin is a potent modulator of microglial gene expression and migration.Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's diseaseLipocalin-type prostaglandin D2 synthase protein regulates glial cell migration and morphology through myristoylated alanine-rich C-kinase substrate: prostaglandin D2-independent effectsCyclic intensive light exposure induces retinal lesions similar to age-related macular degeneration in APPswe/PS1 bigenic miceMicroglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's DiseaseHeparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brainCholesterol: its regulation and role in central nervous system disorders.Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microgliaRelease of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administrationCcr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer's disease).SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantationAutophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide.DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain.Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse modelMulti-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease.
P2860
Q24304041-F9292306-A89E-4409-BF80-76E1F89E57DFQ24604376-BD85E05B-9692-41FD-BE3D-AD81DC698D0AQ27004226-8DD89FEB-A770-4945-9C6B-0B097C4AB0DEQ28084447-1AFC9D1A-EBAE-4A4D-A033-89BED40B55C1Q28274093-EDBF0BED-9FDE-4147-B0DA-D4271456C46AQ28275105-C6606D68-67C3-4869-A3EB-D8B7EEA1910FQ28304401-15DAF31E-0C2B-4C02-953A-80CDA50BB30DQ28552971-8B662F67-613C-4CE7-80D1-D2DF4F678706Q28564803-F1FBFF5E-1B83-461E-838B-167881BED3BBQ29976920-6D5B9688-AEC7-47A1-8331-3596B30171DFQ33641785-0AC1D205-89F3-40EA-A851-C1AB2C3B60C8Q33830137-9034F57B-FD8C-424C-A2FC-8E944AF1A5B9Q34155080-69FAB392-8BDA-43D7-8667-709DD2259AEBQ34291417-04C6AA8D-54E6-4946-AB7E-1BEB20F05BE8Q34383143-55D2B141-FA6B-438A-A784-D1B1859FF5D1Q34612473-78663237-DB16-4C46-99A0-C6857329C836Q34965558-A6C53679-4E54-4CD3-896E-9E61DA14DCC4Q35036100-8B29E957-0762-4A14-B5B3-9EACEC4E94A8Q35162073-07E14CF9-2562-4845-AF51-A0A17AD34BB1Q35165186-93F13576-98A4-4E59-A536-964CA876234AQ35237806-4150CE17-18FC-4CBB-979D-DD685D4F0C4AQ35338546-C0F73AFA-20DC-409C-9545-5060B0E544CAQ35515633-76E76FBD-0DEE-412D-A149-852FC35DA0EDQ35712471-4646EC32-F606-4220-BD90-8BD40945DFF6Q35842012-37227A62-6D39-44BF-8C93-BDE811611D59Q35917824-0D1ED7FB-5B6A-43E0-B31A-802B9765B787Q35999547-B2FEA199-58A2-417D-8E16-2DEF259742FAQ36240868-2D393B17-BDED-44B4-BE9B-421CD2057D4AQ36355194-06F13BF5-C308-4803-A6BA-6706F61A3A5BQ36487090-087056A4-F982-4B51-AABF-CF0BAC00D2A2Q36642679-BA6E211F-D9FE-438F-95E5-A8AD5EE6A083Q36652628-7021750B-AF00-4216-85F6-7F023C846B02Q36710294-89869D8A-1E94-4AE9-942B-2A792117B060Q36841539-7E6CAA50-F9A8-421C-9B64-661399C5FA3EQ36997172-24FD3FBE-0A87-4236-9462-F2EC42949E63Q37116205-9BA35384-BDBC-4BA3-A779-8289279416E5Q37362105-52823C49-250E-4619-886C-0D6E6E387A72Q37527799-0C787569-5CA6-412C-9AAC-958ED3031670Q37559812-82BE7B85-54E5-4C4C-A873-81E04B87800DQ37612968-34D35714-CF7E-4F66-9DB6-10B100932319
P2860
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@en
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@nl
type
label
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@en
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@nl
prefLabel
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@en
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@nl
P1476
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications.
@en
P2093
Andrew D Luster
Joseph El Khoury
P304
P356
10.1016/J.TIPS.2008.08.004
P577
2008-10-01T00:00:00Z